Icodextrin decreases technique failure and improves patient survival in peritoneal dialysis patients. (March 2015)

• Record Type: Journal Article
• Authors: Wang, I‐Kuan; Li, Yu‐Fen; Chen, Jin‐Hua; Liang, Chih‐Chia; Liu, Yao‐Lung; Lin, Hsin‐Hung; Chang, Chiz‐Tzung; Tsai, Wen‐Chen; Yen, Tzung‐Hai; Huang, Chiu‐Ching
• Is Part Of: Nephrology. Volume 20:Number 3(2015)
• Page Start: 161
• Page End: 167
• Publication Date: 2015-03
• Subjects: Nephrology -- Periodicals; Kidneys -- Diseases -- Periodicals; Nephrologists -- Periodicals; 616.61; 616.61
• DOI: 10.1111/nep.12375
• Languages: English
• ISSNs: 1320-5358

Abstract

<abstract abstract-type="main"> <title>Abstract</title> <sec id="nep12375-sec-0001" sec-type="section"> <title>Aim</title> <p>It remains unclear whether long‐term daily icodextrin use can decrease technique failure and improve survival in peritoneal dialysis (PD) patients. The aim of the present study was to investigate whether icodextrin use, once daily, can decrease technique failure and prolong patient survival in incident PD patients.</p> </sec> <sec id="nep12375-sec-0002" sec-type="section"> <title>Methods</title> <p>Incident PD patients who survived more than 90 days were recruited from the China Medical University Hospital, Taiwan, between 1 January 2007 and 31 December 2011. All patients were followed until transfer to haemodialysis (HD), renal transplantation, transfer to another centre, death, or 31 December 2011.</p> </sec> <sec id="nep12375-sec-0003" sec-type="section"> <title>Results</title> <p>A total of 306 incident PD patients (89 icodextrin users, 217 icodextrin non‐users) were recruited during the study period. Icodextrin users were more likely to have hypertension, diabetes and high or high‐average peritoneal transport compared with non‐users. During the follow‐up period, 43 patients were transferred to HD: seven (7.87%) of the icodextrin group, and 36 (16.59%) of the non‐icodextrin group. Thirty‐two patients died during the follow‐up period: five (5.62%) of the icodextrin group, and 27 (12.44%) of the non‐icodextrin group. Icodextrin use was significantly associated with a better prognosis, in terms of technique failure (adjusted HR = 0.32; 95% CI = 0.14–0.72). With regard to patient survival, icodextrin use (adjusted HR = 0.33; 95% CI = 0.12–0.87) was associated with a significantly lower risk of death.</p> </sec> <sec id="nep12375-sec-0004" sec-type="section"> <title>Conclusion</title> <p>The use of icodextrin once daily may decrease technique failure and improve survival in incident PD patients.</p> </sec> </abstract>